TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01137591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APAP and NAC combination
Description: APAP 650mg and NAC 600mg combination oral tablet administered once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: APAP and Placebo
Description: APAP 650mg and Placebo combination oral tablet administered once
Study: NCT03026374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be Resilient to Breast Cancer
Description: This is a supportive-expressive group therapy.
Study: NCT01658774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Single 400mg dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Single 400mg dose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: 500 mg Vitamin C
Study: NCT04024007

Intervention type: DIAGNOSTIC_TEST
Intervention: Citrate dosage
Description: Patients are dialysed according to the standard of care. Biological variables are measured in pre-filter, post-filter and dialysate 30 minutes after the dialysis is initiated.
Study: NCT03133533

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic repair
Description: Surgical inguinal hernia repair using laparoscopic approach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robot-assisted repair
Description: Surgical inguinal hernia repair using robot-assisted approach.
Study: NCT02288195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m² iv drip over 2 hours on day 1, repeated every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 825 mg/m² twice daily administered orally and concurrently with radiation therapy for 5 days per week.~1000 mg/m² po twice daily on days 1- 14 repeated every 21 days in Group A and adjuvant chemotherapy in Group B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 825 mg/m² twice daily administered orally and concurrently with radiation therapy for 5 days per week.~1000 mg/m² po twice daily on days 1- 14 repeated every 21 days in Group A and adjuvant chemotherapy in Group B.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: The total dosage was 46Gy consisted of 23 fractions of 2 Gy to clinical target volume without a boost dose and with the boost 4 Gy consisted of 2 fractions of 2 Gy to gross tumor volume by IMRT or 3D-CRT.
Study: NCT02075463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: Film coated tablets containing 1 mg, 2 mg, 5 mg or 25 mg of GSK1278863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet for GSK1278863
Study: NCT02700776

Intervention type: OTHER
Intervention: Phlebotomy - Blood sampling for GP88 at MM
Description: Women undergoing a screening mammogram will have a blood sample drawn to look for GP88.

Intervention type: OTHER
Intervention: Phlebotomy - Blood sampling for GP88 at MM
Description: Women undergoing a screening mammogram will have a blood sample drawn to look for GP88.

Intervention type: OTHER
Intervention: Phlebotomy - Blood sampling for GP88 at MM
Description: Women undergoing a screening mammogram will have a blood sample drawn to look for GP88.

Intervention type: PROCEDURE
Intervention: SOC Tissue biopsy
Description: standard of care tissue biopsy if clinically indicated.
Study: NCT03174847

Intervention type: PROCEDURE
Intervention: Adrenalectomy
Description: Adrenalectomy for unilateral adrenal hyperplasia / adenoma

Intervention type: DRUG
Intervention: Mineralocorticoid Receptor Antagonists
Description: Medical treatment with MRA / amiloride
Study: NCT00239577

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated tetravalent dengue vaccine
Description: Live attenuated tetravalent dengue vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated tetravalent dengue vaccine
Description: Live attenuated tetravalent dengue vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated tetravalent dengue vaccine
Description: Live attenuated tetravalent dengue vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02704585

Intervention type: DEVICE
Group type: OTHER
Intervention: Nellcor
Description: Measurement of pulse oximetry in the delivery room with Nellcor pulse oximeter

Intervention type: DEVICE
Group type: OTHER
Intervention: Masimo
Description: Measurement of pulse oximetry in the delivery room with Masimo pulse oximeter
Study: NCT03394235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long-pulsed, 1064nm Nd-YAG laser
Description: This long-pulsed Nd-YAG laser is commonly used for laser hair removal and vascular lesions, but in this study it is used to reduce the size of the hair shaft at the occipital area.
Study: NCT01300676

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Tualang honey
Description: This was a randomized, prospective, clinical study to evaluate the effect of Tualang honey in comparison with HRT. Subjects will be confined to healthy postmenopausal women who were naturally menopause for more than one year. The study period was four months. A total of 79 patients were recruited.~Group 1: Subjects receiving 20 g/day of Tualang honey. The honey used was from a single batch honey supplied by Federal Agricultural Marketing Authorities (FAMA), Malaysia, evaporated by FAMA to achieve a water content of about 20%, submitted to Sterile Gamma company at Shah Alam, Selangor for sterilization at 25 kGy and packed in 20 g sachet in collaboration with School of Pharmaceutical Sciences laboratory.~Group 2: Subjects receiving hormonal replacement therapy (Femoston®), also known as Femo conti 1/5 (contain 1 mg Estradiol valerate and 5 mg Dydrogesterone) supplied by Solvay Pharma Malaysia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tualang honey
Description: This was a randomized, prospective, clinical study to evaluate the effect of Tualang honey in comparison with HRT. Subjects will be confined to healthy postmenopausal women who were naturally menopause for more than one year. The study period was four months. A total of 79 patients were recruited.~Group 1: Subjects receiving 20 g/day of Tualang honey. The honey used was from a single batch honey supplied by Federal Agricultural Marketing Authorities (FAMA), Malaysia, evaporated by FAMA to achieve a water content of about 20%, submitted to Sterile Gamma company at Shah Alam, Selangor for sterilization at 25 kGy and packed in 20 g sachet in collaboration with School of Pharmaceutical Sciences laboratory.~Group 2: Subjects receiving hormonal replacement therapy (Femoston®), also known as Femo conti 1/5 (contain 1 mg Estradiol valerate and 5 mg Dydrogesterone) supplied by Solvay Pharma Malaysia.
Study: NCT04270721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The EAGLE Safe Anastomosis Quality Improvement Intervention
Description: The intervention is the same in each arm; the EAGLE Safe Anastomosis Quality Improvement Intervention is an educational programme for behavioural change composed of three parts:~1. Introduction of a routine patient risk stratification for anastomotic leak~2. Implementation of the ESCP Safe Anastomosis Checklist~3. Adoption of a harmonised technique for stapled and handsewn anastomosis based on best evidence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The EAGLE Safe Anastomosis Quality Improvement Intervention
Description: The intervention is the same in each arm; the EAGLE Safe Anastomosis Quality Improvement Intervention is an educational programme for behavioural change composed of three parts:~1. Introduction of a routine patient risk stratification for anastomotic leak~2. Implementation of the ESCP Safe Anastomosis Checklist~3. Adoption of a harmonised technique for stapled and handsewn anastomosis based on best evidence.
Study: NCT03597243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash Transfer
Description: Girls enrolled receive a quarterly direct cash transfer of a total of 70,000 Tshs (30 USD) quarterly through mobile phone based cash transfer over a period of two years, for which they will receive mobile phones and SIM cards form the program.
Study: NCT00546988

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic stem cell transplant
Study: NCT03538327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silybin
Description: After enrollment, all patients were encouraged to make lifestyle changes according with current guidelines, moreover it was also recommended to take silybin coniugated to vitamin E and phosphatidylcholine that shows higher intestinal absorption and bioavailability (Indena, IBI-Lorenzini spa Italy: Realsil®), as granules for oral solution at a dose of 3 g bid. Each subject was re-evaluated monthly performing a clinical examination to consider the opportunity of antihypertensive treatment. Finally, inflammatory, metabolic and hemodynamic parameters were assessed after 6 months of treatment. In particular, at the end of the follow-up period, a new OGTT was performed, to test the effects of silybin on glucose tolerance and IR status.
Study: NCT00906477

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified CI therapy
Description: 10 treatment days 3 hours a day: Shaping exercises 2 hours. Task practice 0,5 hours. Behavioral therapy (Transfer package) 0,5 hour. Encouragement to wear a restraining mitt on the least affected arm for all safe activities.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified CI therapy
Description: 10 treatment days 3 hours a day: Shaping exercises 2 hours. Task practice 0,5 hours. Behavioral therapy (Transfer package) 0,5 hour. Encouragement to wear a restraining mitt on the least affected arm for all safe activities.
Study: NCT05244863

Intervention type: OTHER
Intervention: Test
Description: Measurements
Study: NCT01975948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Health Practice Support Program
Description: 1. training and (2) practice support.~   * Three half day workshop sessions over a 24 week period.~  * Practice support:~     3 evidence based Supported Self Management tools (Cognitive Behavioral Interpersonal Skills Manual,Bounceback program, Antidepressant Skills Workbook), and Practice support coordinator provides guidance to incorporate newly acquired tools, skills, and processes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Health Practice Support Program
Description: 1. training and (2) practice support.~   * Three half day workshop sessions over a 24 week period.~  * Practice support:~     3 evidence based Supported Self Management tools (Cognitive Behavioral Interpersonal Skills Manual,Bounceback program, Antidepressant Skills Workbook), and Practice support coordinator provides guidance to incorporate newly acquired tools, skills, and processes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Physicians manage patients with depression as usual

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Physicians manage patients with depression as usual
Study: NCT00931697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD 452 (+) mefloquine
Description: Single dose delivered as over-encapsulated tablet at ascending doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racemic Mefloquine
Description: Single dose delivered as over-encapsulated tablet at ascending dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Over-encapsulated placebo to maintain blinding
Study: NCT01299454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPC-34712
Description: All groups will receive a single oral 2-mg OPC-34712 dose on Day 1 with 240 mL room temperature still water. Subjects will be administered the OPC-34712 dose in the fasted state (at least 8 hours of fasting) and no food will be allowed for 4 hours postdose. Water will be restricted as part of the dosing procedure from 1 hour prior to dosing and 2 hours post-dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPC-34712
Description: All groups will receive a single oral 2-mg OPC-34712 dose on Day 1 with 240 mL room temperature still water. Subjects will be administered the OPC-34712 dose in the fasted state (at least 8 hours of fasting) and no food will be allowed for 4 hours postdose. Water will be restricted as part of the dosing procedure from 1 hour prior to dosing and 2 hours post-dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPC-34712
Description: All groups will receive a single oral 2-mg OPC-34712 dose on Day 1 with 240 mL room temperature still water. Subjects will be administered the OPC-34712 dose in the fasted state (at least 8 hours of fasting) and no food will be allowed for 4 hours postdose. Water will be restricted as part of the dosing procedure from 1 hour prior to dosing and 2 hours post-dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPC-34712
Description: All groups will receive a single oral 2-mg OPC-34712 dose on Day 1 with 240 mL room temperature still water. Subjects will be administered the OPC-34712 dose in the fasted state (at least 8 hours of fasting) and no food will be allowed for 4 hours postdose. Water will be restricted as part of the dosing procedure from 1 hour prior to dosing and 2 hours post-dose.
Study: NCT03502148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRV111 (Cisplatin Transmucosal System)
Description: Each treatment visit will include one application of a permeation enhancer and then 2, 3 or 5 PRV111 (Cisplatin Transmucosal System) applications depending on the Stage subject is enrolled in.
Study: NCT02124135

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet/Nutrition Education
Description: As described elsewhere, all participants will receive 1 phone call and 3 in person sessions with the registered dietitian.~Participants in the clinic arm will receive the education intervention in the clinic.~Participants in the restaurant arm will receive the education intervention while dining in a restaurant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet/Nutrition Education
Description: As described elsewhere, all participants will receive 1 phone call and 3 in person sessions with the registered dietitian.~Participants in the clinic arm will receive the education intervention in the clinic.~Participants in the restaurant arm will receive the education intervention while dining in a restaurant.
Study: NCT02232776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Dose of Losartan : 0.7mg/kg once daily.
Study: NCT01212848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Group 1: The treatment group will receive the following dose of repetitive TMS delivered over the left prefrontal cortex: 10 Hz, 120% Motor Threshold, 5 second pulse train, 10 second intertrain (IT) interval, 30 minutes of treatment, 6000 pulses per session; three sessions each day (18,000 stimuli) for three days for a total of 54,000 stimuli.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation - Sham Comparator
Description: The control group will receive an identical dosing schedule of sham repetitive TMS over three days.
Study: NCT01621893

Intervention type: PROCEDURE
Intervention: Subchondroplasty
Study: NCT04330534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX9930
Description: BCX9930 capsules for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to match BCX9930 capsules for oral administration
Study: NCT00982397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Protecta VR-ICD
Description: Protecta single-chamber implantable cardioverter defibrillators.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Protecta DR-ICD or CRT-D
Description: Protecta dual-chamber implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators.
Study: NCT02885285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spinning Class
Description: Spinning Class twice a week for six weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Class
Description: Yoga Class twice a week for six weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance Class
Description: Dance Class twice a week for six weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Exercise Class
Description: No exercise class. Subject will continue regular activities for six weeks.
Study: NCT02326935

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose derived mesenchymal cells
Description: Autologous adipose derived mesenchymal cells, 150M cells deployed via two (2) treatments via intravenous injection.
Study: NCT00600561

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MBSR
Description: Mindfulness-Based Stress Reduction Intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: Mindfulness-Based Stress Reduction Intervention
Study: NCT00434616

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous bone marrow cell concentrate transplantation
Description: bone marrow aspiration (240 ml), processing and reinjection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: saline injection
Description: saline injections
Study: NCT03834636

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restorations with nanoparticulated composites and self etch adhesives
Description: The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a self-etching dental adhesive (SingleBond Universal, 3M ESPE), selective enamel etching, and use of a nanoparticulated composite (Z350, 3M ESPE)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restorations with nanoparticulated composites and total-etch adhesives
Description: The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a total-etching dental adhesive (SingleBond 2, 3M ESPE), and use of a nanoparticulated composite (Z350, 3M ESPE)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restorations with nanohybrid composites and self etch adhesives
Description: The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a self-etching dental adhesive (SingleBond Universal, 3M ESPE), selective enamel etching, and use of a nanohybrid composite (IPS Empress Direct, Ivoclar Vivadent).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restorations with nanohybrid composites and total-etch adhesives
Description: The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a total-etching dental adhesive (SingleBond 2, 3M ESPE), and use of a nanohybrid composite (IPS Empress Direct, Ivoclar Vivadent).
Study: NCT00417456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evisit
Description: Asynchronous,remote care delivery via a secure web platform

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Office visit
Description: Conventional office-based care
Study: NCT03538964

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: toric intraocular lens
Description: cataract surgery with implantation of an toric intraocular lens
Study: NCT00433537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study: NCT04534790

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Dose Radiotherapy
Description: anti-inflammatory effect with low-dose radiation to the lungs
Study: NCT03606408

Intervention type: DRUG
Group type: OTHER
Intervention: osilodrostat
Description: osilodrostat, in the form of film coated tablets for oral administration, in the following tablet strengths: 1mg, 5mg, 10mg. Each strength has unique tablet size, colour and imprint.
Study: NCT04358874

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication reconciliation
Description: Medicines currently being taken will be reviewed and compared to the medicines that were prescribed at discharge.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication reconciliation
Description: Medicines currently being taken will be reviewed and compared to the medicines that were prescribed at discharge.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Pressure Management
Description: Blood pressure will be checked at follow-up visits and medicines will be adjusted if blood pressure is above target range (\>160/100)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Pressure Management
Description: Blood pressure will be checked at follow-up visits and medicines will be adjusted if blood pressure is above target range (\>160/100)
Study: NCT03896126

Intervention type: OTHER
Intervention: Observational
Description: There is no intervention. This is an observational study attempting to establish parameters of normal and abnormal vagal tone in healthy control and gastroparesis patients, as there is currently no metric to determine what dose of vagal stimulation is required to treat gastroparesis.

Intervention type: OTHER
Intervention: Observational
Description: There is no intervention. This is an observational study attempting to establish parameters of normal and abnormal vagal tone in healthy control and gastroparesis patients, as there is currently no metric to determine what dose of vagal stimulation is required to treat gastroparesis.
Study: NCT00433537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV